Squarepoint Ops LLC Purchases New Position in Elanco Animal Health Incorporated $ELAN

Key Points

• Squarepoint Ops acquired 133,225 Elanco shares in the second quarter, valued at approximately $3.28 million. Institutional investors collectively own 97.48% of ELAN’s outstanding stock.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus rating and an average price target of $29.09, above the reported $23.19 share price.
• Elanco exceeded quarterly expectations, reporting $0.34 in earnings per share versus the $0.27 consensus and $1.37 billion in revenue, up 10.2% year over year. Company directors also purchased shares recently, contributing to $1.47 million in insider buying over the past three months.

Squarepoint Ops LLC acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 133,225 shares of the company's stock, valued at approximately $3,279,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ELAN. Arizona State Retirement System boosted its position in Elanco Animal Health by 1.0% in the second quarter. Arizona State Retirement System now owns 137,794 shares of the company's stock valued at $3,391,000 after buying an additional 1,316 shares in the last quarter. Nykredit A S acquired a new position in shares of Elanco Animal Health during the second quarter worth $356,000. Corient Private Wealth LP increased its holdings in shares of Elanco Animal Health by 124.1% during the second quarter. Corient Private Wealth LP now owns 342,271 shares of the company's stock worth $8,423,000 after buying an additional 189,540 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Elanco Animal Health in the 2nd quarter valued at $5,214,000. Finally, California State Teachers Retirement System lifted its stake in shares of Elanco Animal Health by 2,358.9% in the 2nd quarter. California State Teachers Retirement System now owns 14,186,139 shares of the company's stock valued at $349,121,000 after acquiring an additional 13,609,203 shares during the last quarter. Institutional investors own 97.48% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ELAN shares. TD Cowen raised their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, June 18th. KeyCorp upped their target price on Elanco Animal Health from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, September 4th. Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Finally, Morgan Stanley boosted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $29.09.

Elanco Animal Health Trading Up 1.5%

Shares of NYSE ELAN opened at $23.19 on Friday. The firm has a 50 day moving average price of $24.54 and a two-hundred day moving average price of $23.93. The stock has a market cap of $11.59 billion, a P/E ratio of -56.57, a price-to-earnings-growth ratio of 1.73 and a beta of 1.68. Elanco Animal Health Incorporated has a 52-week low of $18.22 and a 52-week high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the business earned $0.26 earnings per share. Elanco Animal Health's revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Insider Activity

In related news, Director Lawrence Kurzius bought 40,000 shares of the business's stock in a transaction on Thursday, August 20th. The shares were purchased at an average cost of $23.40 per share, with a total value of $936,000.00. Following the acquisition, the director owned 188,647 shares of the company's stock, valued at $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael Harrington purchased 5,000 shares of Elanco Animal Health stock in a transaction on Wednesday, August 12th. The stock was bought at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the transaction, the director directly owned 131,451 shares in the company, valued at approximately $2,868,260.82. The trade was a 3.95% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is owned by corporate insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated NYSE: ELAN is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company's products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.